Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

The Effect of Cannabis-Based Medicine on Neuropathic Pain and Spasticity in Patients with Multiple Sclerosis and Spinal Cord Injury: Study Protocol of a National Multicenter Double-Blinded, Placebo-Controlled Trial

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Hot and Cold Cognitive Disturbances in Parkinson Patients Treated with DBS-STN: A Combined PET and Neuropsychological Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Bioenergy Crisis in Coronavirus Diseases?

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Calcitonin Gene-Related Peptide (CGRP) and Cluster Headache

    Research output: Contribution to journalReviewResearchpeer-review

  4. Standardization of Data for Clinical Use and Research in Spinal Cord Injury

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Ofatumumab Modulates Inflammatory T Cell Responses and Migratory Potential in Patients With Multiple Sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Pregnancy in women with MS: Impact on long-term disability accrual in a nationwide Danish Cohort

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Ocrelizumab treatment in multiple sclerosis: A Danish population-based cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Disease or acquired damage to the central nervous system frequently causes disabling spasticity and central neuropathic pain (NP), both of which are frequent in multiple sclerosis (MS) and spinal cord injury (SCI). Patients with MS and SCI often request treatment with cannabis-based medicine (CBM). However, knowledge about effects, side effects, choice of active cannabinoids (Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD) alone or in combination), and doses of CBM remains limited. Using a double-blind, parallel design in a national multicenter cohort, this study examines the effect of CBM on spasticity and NP. Patients are randomized to treatment with capsules containing either THC, CBD, THC and CBD, or placebo. Primary endpoints are patient-reported pain and spasticity on a numerical rating scale. Other endpoints include quality of life and sleep, depression and anxiety, and relief of pain and spasticity. Side-effects of CBM are described. In a sub-study, the pharmacodynamics (PD) and pharmacokinetics (PK) of oral capsule CBM are examined. We expect that the study will contribute to the literature by providing information on the effects and side-effects of CBD, THC, and the combination of the two for central neuropathic pain and spasticity. Furthermore, we will describe the PD/PK of THC and CBD in a patient population.

Original languageEnglish
Article number1212
JournalBrain Sciences
Volume11
Issue number9
Number of pages13
ISSN2076-3425
DOIs
Publication statusPublished - 2021

ID: 75774755